Tempest Therapeutics, Inc. (TPST)
Develops experimental drugs targeting cancer cell pathways through small molecule antagonists.
$0.89-0.04%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-88.1%
The outlook
TPST is trading near its 52-week low at $0.89, well below both its 50- and 200-day moving averages. Analyst coverage shows a wide disconnect: the average price target sits roughly 11x higher than the current price, though the stock itself carries a bearish overall score. The data reflects a distressed micro-cap with significant target-price volatility typical of very low-priced stocks.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Price targetAvg target +1131% vs current price
Market cap
$14.3M
52-wk high
$12.23
52-wk low
$0.87
50-day avg
$1.27
200-day avg
$3.34
Trailing P/E
—